In February 2014 the U.S. Food and Drug Administration (FDA) approved ibrutinib as a treatment for patients with chronic lymphocytic leukemia (CLL). This approval is a significant advancement for patients with this blood cancer. LLS funding has supported clinical trials and laboratory studies of ibrutinib for patients with CLL, MCL and other lymphomas. Ibrutinib is now a possible treatment for patients with mantle cell lymphoma (MCL) and CLL who have received at least one prior treatment.
Ibrutinib, which goes by the trade name ImbruvicaTM, is a therapy that targets an enzyme which promotes growth of a variety of B-cell cancers, including CLL, MCL, Waldenstrom’s macroglobulinemia (WM), follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), hairy cell leukemia (HCL) and multiple myeloma.
To find out more about the FDA’s approval of ibrutinib or for more information on this treatment option visit the LLS News Room article here.
-Submitted by Ana Hurtado, Boston Light The Night Walk walker and Hodgkin’s survivor